Trial
NCT03587363
A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib
Phase ITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Janssen Research & Development, LLC
Collaborators
—
Condition
Hepatic Impairment
Intervention
Erdafitinib
Why stopped
Mild/moderate hepatic impairment (HI) cohorts completed with no impact to erdafitinib exposure. Severe HI cohort enrollment stopped early.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-03